| Name | Title | Contact Details |
|---|---|---|
Nancy Saputra |
IT Director, Systems, Cloud, and Information Security | Profile |
Timothy Moore |
Chief Technical Officer | Profile |
Timothy Moore |
Chief Technology Officer | Profile |
Alison Moore |
Chief Technical Officer | Profile |
Alison Moore |
Executive Vice President of Operations and Chief Technical Officer | Profile |
Portage is a unique entity in the world of biotechnology, catalyzing R&D to produce more quality clinical programs and maximize potential returns.
Friendship Health and Rehab Center is a Roanoke, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
United Home Care Services, Inc. is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Miraculins is a pre-revenue biotechnology company that acquires, develops and commercializes new, non-invasive diagnostic and risk assessment tests to aid physicians in the earlier diagnosis of disease. The Company specializes in the development and manufacturing of medical devices and has been successfully accessing capital on the public markets as required to finance its operations to date. It is currently preparing for transition to a commercialization phase. Miraculins began as a research and development company in 2002, with a focus on biomarker discovery. In June of 2008, the company shifted its focus to diagnostic asset development where it began to in-license and acquire diagnostic and risk assessment technologies that had completed early stage research and addressed significant unmet medical needs in the U.S., Canada, and global markets.
Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.